Regenxbio NEW POSITIVE INITIAL EFFICACY DATA FROM DUCHENNE TRIAL

 

• New three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression
  • Patient aged 12 years at dosing had expression level at 75.7% of control
• Early evidence of strength and motor function improvement observed
• On track to initiate pivotal trial in second half of 2024
• Webcast this morning, Tuesday, March 5, 8:30 a.m. ET, with principal investigator

REGENXBIO will host a webcast Tuesday, March 5 at 8:30 a.m. ET. The live webcast can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

https://www.prnewswire.com/news-releases/regenxbio-announces-new-positive-initial-efficacy-data-from-affinity-duchenne-trial-302079525.html